Gilbert A., Lion G. Arterites infectieuses experimentales. C. R. Soc. Biol. Fil. 1889; 41: 583-4.
Danesh J., Collins R., Peto R. Chronic infections and coronary heart disease: is there a link? Lancet. 1997; 350: 430-62.
Boddi M., Abbate R., Chellini B. et al. Hepatitis C virus RNA localization in human carotid plaques. J. Clin. Virol. 2010; 47: 72-5.
Guiltinan A., Kaidarova Z., Custer B. et al. Increased all-cause, liver and cardiac mortality among hepatitis C virus-seropositive blood donors. Am. J. Epidemiol. 2008; 167(6): 743-50.
Butt A.A., Xiaoqiang W., Budoff M. et al. Hepatitis C virus infection and the risk of coronary disease. Clin. Infect. Dis. 2009; 49: 225-32.
Alyan O., Kacmaz F., Ozdemir O. et al. Hepatitis C infection is associated with increased coronary artery atherosclerosis defined by modified reardon severity score system. Circ. J. 2008; 72: 1960-5.
Ishizaka Y., Ishizaka N., Takahashi E. et al. Association between hepatitis C virus core protein and carotid atherosclerosis. Circ. J. 2003; 67: 26-30.
Ishizaka N., Ishizaka Y., Takahashi E. et al. Association between hepatitis C virus seropositivity, carotid-artery plaque, and intimamedia thickening. Lancet. 2002; 359: 133-5.
Shah P.K. Link between infection and atherosclerosis: who are the culprits: viruses, bacteria, both, or neither? Circulation. 2001; 103: 5-6.
Agnello V., Abel G., Elfahal M. et al. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc. Natl. Acad. Sci. USA. 1999; 96: 12766-71.
Peng Y.S., Chiang C.K., Hsu S.P. et al. Influence of hepatitis C virus infection on soluble cellular adhesion molecules in hemodialysis patients. Blood Purif 2005; 23: 106-12.
Vassalle C., Masini S., Bianchi F., Zucchelli G.C. Evidence for association between hepatitis C virus seropositivity and coronary artery disease. Heart. 2004; 90(5): 565-6.
Насонов Е.Л. Иммунологические маркеры атеросклероза. Терапевтический архив. 2002; 5: 80-5.
Насонов Е.Л. Ревматология. Клинические рекомендации. М.: Гэотар-медиа; 2010.
Wick G., Romen M., Amberger A. et al. Atherosclerosis, autoimmunity and vascular-associated lymphoid tissue. FASEB J. 1997; 11: 1199-207.
Turesson C., Jacobsson L.T., Matteson E.L. Cardiovascular co-morbidity in rheumatic diseases. Vasc. Hlth Risk Manag. 2008; 4: 605-14.
Shoenfeld Y., Gerli R., Dorial A. et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation. 2005; 112: 3337-47.
Корнеева О.Н., Драпкина О.М. Неалкогольная жировая болезнь печени у пациентов с метаболическим синдромом. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2007; 17 (1, прил. 29): 65.
Корнеева О.Н., Драпкина О.М., Буеверов А.О., Ивашкин В.Т. Неалкогольная жировая болезнь печени как проявление метаболического синдрома. Клинические перспективы гастроэнтерологии, гепатологии. 2005; 4: 24.
Драпкина О.М., Корнеева О.Н. Неалкогольная жировая болезнь печени и сердечно-сосудистый риск: влияние женского пола. Фарматека. 2010; 15: 28-33.
Adinolfi L.E., Restivo L., Zampino R. et al. Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV - related steatosis. Atherosclerosis. 2012; 221: 496-502.
Miyajima I., Kawaguchi T., Fukami A. et al. Chronic HCV infection was associated with severe insulin resistance and mild atherosclerosis: a population-based study in an HCV hyperendemic area. J. Gastroenterol. 2013; 48: 92-100.